Dacogen

(Decitabine)

ApprovedSmall molecule

Decitabine is used to treat certain blood cancers, particularly myelodysplastic syndromes (abnormal blood cell development). It works by helping to restore normal function to blood-forming cells that have become abnormal.[2] Dacogen is currently approved and in use across 58 indications[4].[1]

Dacogen is one of 883 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.

Indications

321

Total Trials

Active Trials

882

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Non-Hodgkins LymphomaApproved

ParagangliomaApproved

Nasopharyngeal CarcinomaApproved

Lymphoblastic LymphomaUnknown status

Unspecified Peripheral T-Cell LymphomaApproved

Primary MyelofibrosisActive, not recruiting

Systemic MastocytosisRecruiting

LymphomaUnknown status

Head and Neck Malignant NeoplasiaApproved

Refractory Anemia With Excess BlastsActive, not recruiting

Non-Hodgkins LymphomaApproved

Approved

ParagangliomaApproved

Approved

Nasopharyngeal CarcinomaApproved

Approved

Lymphoblastic LymphomaApproved

Unknown status

Unspecified Peripheral T-Cell LymphomaApproved

Approved

Primary MyelofibrosisPhase 2

Active, not recruiting

Systemic MastocytosisPhase 1

Recruiting

LymphomaApproved

Unknown status

Head and Neck Malignant NeoplasiaApproved

Approved

Refractory Anemia With Excess BlastsApproved

Active, not recruiting

Showing 10 of 58 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Adenocard

2 3

Lexiscan

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Spravato

WWim Janssens

Preclinical

2 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

AIN

NCT04229979

Q1 2027

Phase 1Active, not recruiting

MDS

NCT03974217

Phase 2Active, not recruiting

Acute Myeloid Leukemia

NCT01627041

Phase 2Recruiting

Relapsed/refractory AML

NCT06156579

Phase 1Recruiting

Study completion

NCT06327685

Phase 2Recruiting

MDS

NCT05184842

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia39 trials

Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients

Unknown status·JJianxiang Wang·Phase 3·NCT01633099·46 enrolled

Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia

Completed·UUniversity Hospital Freiburg·Phase 2·NCT00867672·204 enrolled

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·DDavid Iberri·Phase 2·NCT01846624·13 enrolled

Show 36 more trials

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Unknown status·CChunyan Ji·Phase 3·NCT02985372·30 enrolled

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·BBhavana Bhatnagar·Phase 1·NCT02093403·25 enrolled

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting·BBio-Path Holdings, Inc.·Phase 1·NCT05190471·48 enrolled

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT02029417·2 enrolled

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1/2·NCT02632721·49 enrolled

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

Completed·—·Phase 1/2·NCT01690507·29 enrolled

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01420926·165 enrolled

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00703300·19 enrolled

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02954653·8 enrolled

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT04146038·5 enrolled

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Completed·UUniversity of Nebraska·Phase 2·NCT03226418·75 enrolled

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00416598·546 enrolled

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·SSumithira Vasu·Phase 1·NCT02316964·8 enrolled

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

Terminated·YYale University·Phase 2·NCT04051996·1 enrolled

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Completed·CCardiff Oncology·Phase 1/2·NCT03303339·72 enrolled

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT02996474·10 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02441803·11 enrolled

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Suspended· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04485052·222 enrolled

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT00398983·50 enrolled

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Terminated·KKartos Therapeutics, Inc.·Phase 1/2·NCT04113616·70 enrolled

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01627041·178 enrolled

A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·UUniversity of Rochester·Phase 1·NCT00861874·13 enrolled

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01352650·71 enrolled

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

Unknown status·HHuihan Wang·Phase 3·NCT05382390·130 enrolled

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03164057·206 enrolled

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00492401·55 enrolled

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

Completed· Eisai logo

Eisai·Phase 2·NCT00358644·55 enrolled

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01786343·74 enrolled

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 2·NCT03063203·17 enrolled

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·EECOG-ACRIN Cancer Research Group·Phase 3·NCT02085408·727 enrolled

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Terminated·MMayo Clinic·Phase 2·NCT02634827·1 enrolled

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02257138·30 enrolled

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03041688·58 enrolled

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Recruiting·BBrian Jonas·Phase 2·NCT04905810·20 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT05449899·232 enrolled

Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients

Completed·UUniversity of Utah·Phase 1·NCT01149408·3 enrolled

Myelodysplastic Syndrome29 trials

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT03092674·76 enrolled

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

Completed·WWashington University School of Medicine·Phase 1·NCT00986804·24 enrolled

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT04245397·151 enrolled

Show 26 more trials

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed· Pfizer logo

Pfizer·Phase 2·NCT01546038·255 enrolled

Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT01809392·15 enrolled

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed·—·Phase 1/2·NCT01165996·25 enrolled

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Completed· Amgen logo

Amgen·Phase 2·NCT00321711·69 enrolled

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Unknown status·SShanghai Tong Ren Hospital·Phase 2·NCT03356080·50 enrolled

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01893320·66 enrolled

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

No longer available· Johnson & Johnson logo

Johnson & Johnson··NCT01026376

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02010645·6 enrolled

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067808·128 enrolled

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Active, not recruiting·TThomas Jefferson University·Phase 1·NCT05564650·6 enrolled

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Withdrawn·LLi Junmin·Phase 3·NCT03377725

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01812252·50 enrolled

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01130506·17 enrolled

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02564536

Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003361·75 enrolled

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Recruiting·PPureTech·Phase 1·NCT05829226·90 enrolled

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01567059·34 enrolled

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01834248·9 enrolled

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00778375·122 enrolled

Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure

Unknown status·KKing's College London·Phase 2·NCT01133886·50 enrolled

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00043134·220 enrolled

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03358719·8 enrolled

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01400633·156 enrolled

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02269280·185 enrolled

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed· Eisai logo

Eisai·Phase 1·NCT01378416·16 enrolled

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

Unknown status·CCttq·Phase 4·NCT02013102·240 enrolled

Myelodysplastic Syndromes10 trials

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·WWashington University School of Medicine·Phase 2·NCT01687400·114 enrolled

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01593670·9 enrolled

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00075010·54 enrolled

Show 7 more trials

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Withdrawn· Takeda logo

Takeda·Phase 2·NCT04985656

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Completed·WWashington University School of Medicine·Phase 1/2·NCT00691938·52 enrolled

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT01806116·30 enrolled

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01729845·52 enrolled

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02469415·3 enrolled

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Recruiting·WWest Virginia University·Phase 1/2·NCT06923488·26 enrolled

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00382200·54 enrolled

Lymphoma7 trials

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Unknown status·SSouthwest Hospital, China·Phase 3·NCT03553537·100 enrolled

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT03250962·280 enrolled

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Unknown status·MMingzhi Zhang·Phase 4·NCT03579082·60 enrolled

Show 4 more trials

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00109824·42 enrolled

Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas

Unknown status·HHan weidong·Phase 1/2·NCT01799083·100 enrolled

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00089089·42 enrolled

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04279379·20 enrolled

Conditioning6 trials

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02744742·202 enrolled

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04098653·196 enrolled

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Completed·RRadboud University Medical Center·Phase 2·NCT02252107·46 enrolled

Show 3 more trials

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04123392·196 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT05453552·242 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04713956·242 enrolled

72 more indications

Acute Leukemia5 trials

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01794702·65 enrolled

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03596892·122 enrolled

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Unknown status·PPeking University People's Hospital·Phase 2/3·NCT03799224·55 enrolled

Show 2 more trials

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT05805072·20 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002831·24 enrolled

Leukemia4 trials

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Completed·FFox Chase Cancer Center·Phase 2·NCT02190695·92 enrolled

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Terminated· Eisai logo

Eisai·Phase 2·NCT01177540·25 enrolled

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00349596·40 enrolled

Show 1 more trial

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Terminated· AbbVie logo

AbbVie·Phase 1·NCT02203773·212 enrolled

MDS4 trials

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Terminated· Novartis logo

Novartis·Phase 2·NCT04878432·39 enrolled

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Recruiting·MMontefiore Medical Center·Phase 2·NCT05184842·91 enrolled

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Active, not recruiting·—·Phase 1·NCT03974217·13 enrolled

Show 1 more trial

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Terminated· Eisai logo

Eisai·Phase 4·NCT01011283·26 enrolled

Chronic Myelogenous Leukemia4 trials

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00275080·80 enrolled

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01498445·32 enrolled

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Completed·AAstex Pharmaceuticals, Inc.·Phase 2·NCT00042003·40 enrolled

Show 1 more trial

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Completed·AAstex Pharmaceuticals, Inc.·Phase 2·NCT00042016·40 enrolled

Fallopian Tube Cancer3 trials

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01673217·18 enrolled

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT03017131·9 enrolled

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Terminated·CCancer Research UK·Phase 2·NCT00748527·134 enrolled

High Risk3 trials

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Completed· Novartis logo

Novartis·Phase 1·NCT03066648·241 enrolled

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT04097470·140 enrolled

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

Completed·UUniversity of Rochester·Phase 1/2·NCT02109744·27 enrolled

Ovarian Cancer3 trials

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Recruiting·LLoyola University·Phase 2·NCT05983276·40 enrolled

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

Completed·IIndiana University·Phase 1/2·NCT00477386·28 enrolled

Pancreatic Cancer3 trials

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Completed·MMohammed Milhem·Phase 1·NCT02959164·36 enrolled

Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer

Unknown status·TThe First Hospital of Jilin University·N/A·NCT02685228·20 enrolled

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

Terminated·LLuca Cardone·Phase 2·NCT05360264·7 enrolled

Chemotherapy3 trials

Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice

Unknown status·UUlsan University Hospital··NCT02698124·136 enrolled

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Recruiting· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 3·NCT05586074·324 enrolled

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

Efficacy and Safety2 trials

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Not yet recruiting·RRuijin Hospital·Phase 3·NCT06297772·220 enrolled

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Unknown status·SShandong University·Phase 2·NCT03045510·50 enrolled

Melanoma2 trials

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Completed·CCalifornia Cancer Consortium·Phase 1·NCT00002980

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00791271·17 enrolled

Non-Small Cell Lung Cancer2 trials

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00084981·25 enrolled

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT03233724·9 enrolled

Relapsed or Refractory2 trials

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04493099

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling by invitation·BBGI, China·Phase 1·NCT06499025·16 enrolled

AML2 trials

"InDACtion" vs "3+7" Induction in AML

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT02172872·606 enrolled

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

Completed·SSarit Assouline·Phase 2·NCT02073838·23 enrolled

Newly Diagnosed2 trials

Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

Terminated·EEmory University·Phase 1·NCT02234037·3 enrolled

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT02921061·28 enrolled

Stem Cell Transplant2 trials

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Withdrawn·NNorthside Hospital, Inc.·Phase 2·NCT06337331

Efficacy2 trials

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06441097·152 enrolled

Efficacy of Decitabine in Clearance of MRD

Withdrawn·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03021395

Myeloid Malignancies2 trials

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Completed·MMayo Clinic·Phase 1·NCT02129101·63 enrolled

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT07052422·160 enrolled

Chronic Myelomonocytic Leukemia2 trials

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Completed·GGroupe Francophone des Myelodysplasies·Phase 2·NCT01098084·41 enrolled

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia

Completed·FFondazione Italiana Sindromi Mielodisplastiche-ETS·Phase 2·NCT01251627·43 enrolled

Thalassemia2 trials

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Completed·CCarelon Research··NCT00000623·1,000 enrolled

Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

Completed·CCarelon Research·Phase 2·NCT00661726·6 enrolled

Acute Lymphoblastic Leukemia2 trials

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00882206·15 enrolled

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00042796·21 enrolled

Randomized2 trials

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

Completed·GGroupe Francophone des Myelodysplasies·Phase 3·NCT02214407·170 enrolled

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

Completed·EEpiDestiny, Inc.·Phase 1·NCT03828084·16 enrolled

Phase 21 trial

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Completed·HHelsinn Healthcare SA·Phase 2·NCT01993641·45 enrolled

Induction Chemotherapy1 trial

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Completed·WWeill Medical College of Cornell University·Phase 1·NCT00538876·30 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·RRuijin Hospital·Phase 2/3·NCT06972641·126 enrolled

Relapsed/Refractory AML1 trial

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

Recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT06156579·27 enrolled

Lymphoid Malignancies1 trial

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Completed·YYogen Saunthararajah·Phase 1·NCT02846935·7 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia

Unknown status·—··NCT03687463·6 enrolled

Immune Thrombocytopenia1 trial

A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Completed·SShandong University·Phase 2·NCT01568333·45 enrolled

Relapse1 trial

Epigenetic Reprogramming in Relapse AML

Terminated·MMichael Burke·Phase 1·NCT02412475·3 enrolled

Allogeneic Stem Cell Transplantation1 trial

Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03663751·14 enrolled

Oral1 trial

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Completed·EEpiDestiny, Inc.·Phase 1·NCT05816356·10 enrolled

AML/MDS1 trial

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04055844·14 enrolled

Relapsed/Refractory1 trial

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Unknown status·—·Phase 1/2·NCT03346642·30 enrolled

Sickle Cell Disease1 trial

Decitabine for High-Risk Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01375608·10 enrolled

Myeloid Neoplasm1 trial

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled

Hematological Malignancies1 trial

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05740449

Malignant Tumors1 trial

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

Unknown status·LLi Yu·Phase 3·NCT04292769·200 enrolled

Myeloproliferative Disorder1 trial

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00114257·36 enrolled

Age1 trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06511882·37 enrolled

Advanced Hematologic Malignancies1 trial

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Active, not recruiting·FFoghorn Therapeutics Inc.·Phase 1·NCT04891757·144 enrolled

Chronic Lymphocytic Leukemia1 trial

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079378·84 enrolled

Advanced Malignancies1 trial

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Terminated· Novartis logo

Novartis·Phase 1/2·NCT02608268·252 enrolled

Metastatic Melanoma1 trial

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Completed·HHussein Tawbi·Phase 1/2·NCT00715793·39 enrolled

Malignancies1 trial

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00037817·34 enrolled

Arsenic Trioxide1 trial

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

Unknown status·RRuijin Hospital·Phase 1·NCT03855371·5 enrolled

AIN1 trial

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting·SSellas Life Sciences Group·Phase 3·NCT04229979·127 enrolled

Hematologic Cancer1 trial

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357708·50 enrolled

Colorectal Cancer1 trial

Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)

Completed·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT02316028·11 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

Prostate Cancer1 trial

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Withdrawn·RRoswell Park Cancer Institute·Phase 1/2·NCT03709550

Aplastic Anemia1 trial

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04854889·3 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Withdrawn·—·Phase 1·NCT06572631

Metastatic Solid Tumors1 trial

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00701298·30 enrolled

Patients With Advanced Solid Tumors1 trial

Decitabine in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00030615·24 enrolled

Treatment1 trial

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Completed·JJohn Mascarenhas·Phase 1/2·NCT02076191·49 enrolled

Refractory AML1 trial

Epigenetic Reprogramming in Relapse/Refractory AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT03263936·37 enrolled

Trial1 trial

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Terminated·DDelta-Fly Pharma, Inc.·Phase 3·NCT03926624·167 enrolled

Adult AML1 trial

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT03113071·1 enrolled

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Unknown status·—·Phase 1/2·NCT04553393·80 enrolled

Untreated AML1 trial

Decitabine and Talazoparib in Untreated AML and R/R AML

Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT02878785·25 enrolled

Acute Respiratory Distress Syndrome1 trial

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

Suspended·JJohns Hopkins University·Phase 2·NCT04482621·33 enrolled

Phase IB1 trial

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Completed·BBerGenBio ASA·Phase 1/2·NCT02488408·122 enrolled

Older Patients1 trial

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT02532010·13 enrolled

Frontline1 trial

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Withdrawn·UUniversity of Florida·Phase 2·NCT05766514

Celecoxib1 trial

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT02839694

Immunotherapy1 trial

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

Completed·—·Phase 2·NCT02664181·13 enrolled

Metastatic Head and Neck Cancer1 trial

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Completed·MMassachusetts General Hospital·Phase 1·NCT03019003·13 enrolled

Advanced1 trial

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Completed·AAstex Pharmaceuticals, Inc.·Phase 3·NCT00043381·160 enrolled

Lymphoblastic Lymphoma1 trial

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06686108·59 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Unknown status·FFudan University·Phase 2·NCT05638984·60 enrolled

Unspecified2 trials

Avapritinib With Decitabine in Patients With SM-AHN

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06327685·34 enrolled

Phase I, Dose Escalation Study of Decitabine

Completed·UUniversity of Florida·Phase 1·NCT02264873·3 enrolled

Regulatory

FDA Approval Timeline[5]

May 2, 2006

DACOGEN

NDA NDA021790

Jan 28, 2014

DECITABINE

NDA NDA205582

Sources

References

[1]
ClinicalTrials.gov — 321 trial records for Decitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Dacogen drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Decitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Decitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA205582). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sun Pharmaceutical Industries, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA (cytosine-5)-Methyltransferase 1 Inhibitor; DNA (cytosine-5)-Methyltransferase 3a Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sun Pharmaceutical Industries, Inc.